Atara Biotherapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-31$18.09 RISE2026-04-29$4.60 PEAK2026-05-28$11.26 148d | -74.6% 119d | Missed | Missed | — | — | +144.8% 29d | Missed |
DROP2025-12-31$18.09 RISE2026-03-30$4.32 PEAK2026-05-28$11.26 148d | -76.1% 89d | Missed | Missed | — | — | +160.6% 59d | Missed |
DROP2025-12-31$18.09 RISE2026-02-20$4.18 PEAK2026-05-13$10.48 133d | -76.9% 51d | Missed | Missed | — | — | +150.7% 82d | Missed |
DROP2025-12-31$18.09 RISE2026-01-20$4.32 PEAK2026-03-12$6.90 71d | -76.1% 20d | Missed | Missed | — | — | +59.7% 51d | Missed |
DROP2025-10-09$16.08 RISE2025-11-05$10.75 PEAK2025-12-31$18.09 83d | -33.1% 27d | Missed | Missed | — | — | +68.3% 56d | Missed |
DROP2025-06-09$9.26 RISE2025-06-30$7.72 PEAK2025-09-24$14.26 107d | -16.6% 21d | Missed | Missed | — | — | +84.7% 86d | Missed |
DROP2025-01-06$18.00 RISE2025-04-10$5.30 PEAK2025-07-08$9.27 183d | -70.6% 94d | Missed | Missed | — | — | +74.9% 89d | Missed |
DROP2025-01-06$18.00 RISE2025-01-21$6.05 PEAK2025-02-06$10.51 31d | -66.4% 15d | Missed | Missed | — | — | +73.7% 16d | Missed |
DROP2024-05-24$15.60 RISE2024-10-03$7.20 PEAK2024-11-13$14.26 173d | -53.8% 132d | Missed | Missed | — | — | +98.1% 41d | Missed |
DROP2024-04-24$17.88 RISE2024-09-03$6.81 PEAK2024-11-13$14.26 203d | -61.9% 132d | Missed | Missed | — | — | +109.4% 71d | Missed |
DROP2024-02-20$21.00 RISE2024-06-26$7.30 PEAK2024-07-16$12.27 147d | -65.3% 127d | Missed | Missed | — | — | +68.2% 20d | Missed |
DROP2023-11-07$33.25 RISE2024-03-18$14.90 PEAK2024-04-04$19.48 149d | -55.2% 132d | Missed | Missed | — | — | +30.7% 17d | Missed |
DROP2023-09-22$44.75 RISE2024-01-03$11.00 PEAK2024-02-02$30.50 133d | -75.4% 103d | Missed | Missed | — | — | +177.3% 30d | Missed |
DROP2023-08-03$57.75 RISE2023-11-10$5.75 PEAK2024-02-02$30.50 183d | -90.0% 99d | Missed | Missed | — | — | +430.4% 84d | Missed |
DROP2023-04-21$76.00 RISE2023-08-21$35.25 PEAK2023-09-22$44.75 154d | -53.6% 122d | Missed | Missed | — | — | +27.0% 32d | Missed |
1–15 / 29 1 / 2 | |||||||
Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara...
Atara Biotherapeutics Inc: Atara Biotherapeutics Inc - may offer up to $79.27 million in common stock as of May 12, 2026 - SEC filing...
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 27.5 percent. This is a 108.29 percent decrease over earnings of $3.50 per share
https://www.sec.gov/Archives/edgar/data/1604464/000119312526219518/atra-424-b5-2026_q2.htm
THOUSAND OAKS, Calif. — THOUSAND OAKS, Calif. — Atara Biotherapeutics Inc. on Tuesday reported a first-quarter loss of $4.1 million, after reporting a profit in the same period a year earlier....
Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara...
FDA drug approvals are reshaping biotech stocksâtrack key decisions, FDA leadership turmoil, and volatility. Click for a look at the issues surrounding the FDA.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara ...
Unusual volume stocks in Friday's session
Canaccord Genuity analyst John Newman upgrades Atara Biotherapeutics (NASDAQ:ATRA) from Hold to Buy and raises the price target from $6 to $13.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent Complete Response Letter. Key Investor TakeawaysAtara Biotherapeutics (NASDAQ:ATRA) said the FDA discussed a potential resubmission path for tabelecleucel following a Type A meeting.
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ATRA | +114.49% | +114.05% | -41.90% | +34.74% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +111.52% | +119.77% | -38.46% | +22.06% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Citadel | multi-strat | 194.3K | $918.87K | 0.00% | Added+961.8% | 2026-03-31 |
| StateStreet | passive | 26.5K | $125.12K | 0.00% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 16.2K | $76.81K | 0.00% | Trimmed-5.4% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -0.35 | — | — |
| 2026-03-16 | -0.10 | -0.35 | -238.72% |
| 2025-11-12 | -0.66 | -0.32 | +51.88% |
| 2025-08-11 | -0.32 | 0.19 | +159.38% |
| 2025-05-15 | -1.92 | 3.50 | +281.82% |
| 2025-03-07 | -3.49 | -1.19 | +65.88% |
| 2024-11-12 | -3.50 | -2.93 | +16.24% |
| 2024-08-12 | -2.24 | -3.10 | -38.52% |
| 2024-05-09 | -6.42 | -5.75 | +10.39% |
| 2024-03-28 | -12.05 | -14.00 | -16.18% |
| 2023-11-01 | -16.40 | -16.50 | -0.61% |
| 2023-08-08 | -16.51 | -17.00 | -2.94% |
| 2023-05-08 | -9.51 | -18.00 | -89.28% |
| 2023-02-08 | -9.70 | -18.00 | -85.62% |
| 2022-11-08 | -19.34 | -20.50 | -6.00% |
| 2022-08-08 | -20.26 | -7.82 | +61.39% |